Impact of A. Lumbricoides on Pulmonary Aspergillosis Development
NCT ID: NCT05783544
Last Updated: 2023-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
200 participants
INTERVENTIONAL
2015-05-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacological Evaluation of Antifungal in Chronic Pulmonary Aspergillosis
NCT05064605
An Atlas of Airways at a Single Cell Level in Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Controls
NCT04529993
Prospective Cohort Study of Molecular Mechanism of Lower Respiratory Tract Microbes in Patients With AECOPD
NCT04259736
Aspergillus and Chronic Obstructive Pulmonary Disease Evolution
NCT03646851
Sputum Microbiota and the Association With Clinical Parameters in Steady-state, Acute Exacerbation and Convalescence of Bronchiectasis
NCT02315547
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COPD patients without any comorbidities
Interleukin-1B
Level of serum interleukin-1B will be detected
Interleukin-4
Level of serum interleukin-4 will be detected
Interleukin-6
Level of serum interleukin-4 will be detected
tumor necrosis factor - a
Level of serum tumor necrosis factor - a will be detected
interferon- gamma
Level of serum interferon- gamma will be detected
COPD patients with chronic pulmonary aspergillosis
Interleukin-1B
Level of serum interleukin-1B will be detected
Interleukin-4
Level of serum interleukin-4 will be detected
Interleukin-6
Level of serum interleukin-4 will be detected
tumor necrosis factor - a
Level of serum tumor necrosis factor - a will be detected
interferon- gamma
Level of serum interferon- gamma will be detected
COPD patients with ascariasis
Interleukin-1B
Level of serum interleukin-1B will be detected
Interleukin-4
Level of serum interleukin-4 will be detected
Interleukin-6
Level of serum interleukin-4 will be detected
tumor necrosis factor - a
Level of serum tumor necrosis factor - a will be detected
interferon- gamma
Level of serum interferon- gamma will be detected
COPD patients with chronic pulmonary aspergillosis and ascariasis
Interleukin-1B
Level of serum interleukin-1B will be detected
Interleukin-4
Level of serum interleukin-4 will be detected
Interleukin-6
Level of serum interleukin-4 will be detected
tumor necrosis factor - a
Level of serum tumor necrosis factor - a will be detected
interferon- gamma
Level of serum interferon- gamma will be detected
healthy control
Interleukin-1B
Level of serum interleukin-1B will be detected
Interleukin-4
Level of serum interleukin-4 will be detected
Interleukin-6
Level of serum interleukin-4 will be detected
tumor necrosis factor - a
Level of serum tumor necrosis factor - a will be detected
interferon- gamma
Level of serum interferon- gamma will be detected
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interleukin-1B
Level of serum interleukin-1B will be detected
Interleukin-4
Level of serum interleukin-4 will be detected
Interleukin-6
Level of serum interleukin-4 will be detected
tumor necrosis factor - a
Level of serum tumor necrosis factor - a will be detected
interferon- gamma
Level of serum interferon- gamma will be detected
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* COPD patients with aspergillosis
* COPD patients with ascariasis
* COPD patients with mix-infection
* Healthy individuals (controls)
Exclusion Criteria
* COPD patients with oncological diseases
* COPD patients with other co-infections
30 Years
100 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Svetlana Osipova, MD, PhD, DS
Head of Department of Immunology of Parasitic and Fungal Diseases
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research institute of epidemiology, microbiology and infectious diseases
Tashkent, Uchtepa, Uzbekistan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01032023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.